Unknown

Dataset Information

0

Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies.


ABSTRACT: Avadomide is a cereblon E3 ligase modulator and a potent antitumor and immunomodulatory agent. Avadomide trials are challenged by neutropenia as a major adverse event and a dose-limiting toxicity. Intermittent dosing schedules supported by preclinical data provide a strategy to reduce frequency and severity of neutropenia; however, the identification of optimal dosing schedules remains a clinical challenge. Quantitative systems pharmacology (QSP) modeling offers opportunities for virtual screening of efficacy and toxicity levels produced by alternative dose and schedule regimens, thereby supporting decision-making in translational drug development. We formulated a QSP model to capture the mechanism of avadomide-induced neutropenia, which involves cereblon-mediated degradation of transcription factor Ikaros, resulting in a maturation block of the neutrophil lineage. The neutropenia model was integrated with avadomide-specific pharmacokinetic and pharmacodynamic models to capture dose-dependent effects. Additionally, we generated a disease-specific virtual patient population to represent the variability in patient characteristics and response to treatment observed for a diffuse large B-cell lymphoma trial cohort. Model utility was demonstrated by simulating the avadomide effect in the virtual population for various dosing schedules and determining the incidence of high-grade neutropenia, its duration, and the probability of recovery to low-grade neutropenia.

SUBMITTER: Abbiati RA 

PROVIDER: S-EPMC8397660 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies.

Abbiati Roberto A RA   Pourdehnad Michael M   Carrancio Soraya S   Pierce Daniel W DW   Kasibhatla Shailaja S   McConnell Mark M   Trotter Matthew W B MWB   Loos Remco R   Loos Remco R   Santini Cristina C CC   Ratushny Alexander V AV  

The AAPS journal 20210827 5


Avadomide is a cereblon E3 ligase modulator and a potent antitumor and immunomodulatory agent. Avadomide trials are challenged by neutropenia as a major adverse event and a dose-limiting toxicity. Intermittent dosing schedules supported by preclinical data provide a strategy to reduce frequency and severity of neutropenia; however, the identification of optimal dosing schedules remains a clinical challenge. Quantitative systems pharmacology (QSP) modeling offers opportunities for virtual screeni  ...[more]

Similar Datasets

| S-EPMC4215876 | biostudies-literature
| S-EPMC4809626 | biostudies-literature
| S-EPMC7679128 | biostudies-literature
| S-EPMC4747255 | biostudies-literature
| S-EPMC7983940 | biostudies-literature
| S-EPMC11812934 | biostudies-literature
| S-EPMC3600758 | biostudies-other
| S-EPMC5572374 | biostudies-literature
| S-EPMC7983876 | biostudies-literature
| S-EPMC6618253 | biostudies-literature